Board Committee changes

Vectura Group plc

Board Committee changes post completion of merger with Skyepharma

Chippenham, UK - 5 July 2016: Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading inhaled airways disease focused business, announces the following changes to the composition of its Board Committees.

Audit Committee: Thomas Werner and Frank Condella, the Non-Executive Directors joining the Board following the merger with Skyepharma PLC, become members along with the existing Non-Executive Director, Per-Olof Andersson. Sue Foden steps down from the Committee. The following are now members of the Audit Committee: Neil Warner (Chair), Per-Olof Andersson, Frank Condella and Thomas Werner.

Nomination Committee: Per-Olof Andersson and Frank Condella join the Committee. Neil Warner leaves. The following are now members of the Nomination Committee: Bruno Angelici (Chair), Per-Olof Andersson, Frank Condella and Sue Foden.

Remuneration Committee: Thomas Werner joins the Committee. The following are now members of the Remuneration Committee: Sue Foden (Chair), Bruno Angelici, Neil Warner and Thomas Werner.

In addition, the Company announces that John Brown, the Senior Non-Executive Director of the Company, and a member of the Nomination, Remuneration and Audit Committees ceased to be a Company Committee member with effect from the same date. The Company has previously announced that John Brown would step down from the Board within one month after completion of the merger with Skyepharma PLC and a separate announcement will be made on this in due course.

This information is disclosed to the London Stock Exchange in accordance with the requirements under paragraph 9.6.11R of the United Kingdom Listing Rules relating to the disclosure of changes to the roles, functions and responsibilities of directors.

- Ends -

Enquiries

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.  In June 2016 Vectura completed a merger with Skyepharma PLC.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com